Eisai

News

Closeup of X-ray photography of human brain

Biogen tweaks confirmatory trial of Alzheimer's drug Aduhelm

Biogen and Eisai have expanded the size of the confirmatory trial of their Alzheimer's drug Aduhelm in order to "strengthen the data" for the drug.

News

Medicare limits Aduhelm coverage to clinical trial participa...

Biogen's difficult launch of controversial Alzheimer's therapy Aduhelm has been made even harder by a proposal by Medicare to cover the drug only for certain patients enrolled in clinical t

News

Dream result for Idorsia as FDA clears its insomnia drug

Swiss biotech Idorsia has claimed FDA approval for its first product – insomnia treatment Quviviq – setting up a market challenge to class rivals from Merck & Co and Eisai.

News

Roivant joins RNA splicing push with Eisai deal

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugm

News

Biogen, Eisai Alzheimer's drug lecanemab fast tracked by FDA

Biogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer's programmes, as the FDA awards a fast-track designation to lecanemab, their follow-up t

News

Japan looks set to follow EU in rejecting Alzheimer's drug A...

The Japanese regulator looks like it could follow the European Commission and reject approval of Biogen and Eisai's Alzheimer's disease therapy Aduhelm, leaving the FDA an outlier in its st

Biogen tweaks confirmatory trial of Alzheimer's drug Aduhelm

Medicare limits Aduhelm coverage to clinical trial participa...

Dream result for Idorsia as FDA clears its insomnia drug

Roivant joins RNA splicing push with Eisai deal

Biogen, Eisai Alzheimer's drug lecanemab fast tracked by FDA

Japan looks set to follow EU in rejecting Alzheimer's drug A...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Eisai

Editor's Picks